XHANCE Xtended Patient Support

Utilize the XHANCE Preferred Pharmacy Network (PPN) to help make treatment affordable for your eligible commercially insured patients

Savings in out-of-pocket costs through the XHANCE PPN*

Eligible commercially insured patients with coverage for XHANCE pay as little as:
Initial prescription	$0
Refills through a qualifying refill program in the XHANCE PPN	$0
Refills not through a qualifying refill program	$25 or less per fill

Eligible commercially insured patients without coverage for XHANCE pay as little as:
Initial prescription	$25^† per unit
Refills	$50 per unit

*These offers are not valid for use by cash-paying patients or patients enrolled in Medicare, Medicaid, and TRICARE or other federal or state programs. Offers are subject to quantity limitations. Maximum benefits per fill apply. Patient cost share may impact benefits and eligibility. Optinose® reserves the right to rescind, revoke, or amend this offer without notice. Click here for additional terms and conditions.

^†Eligible commercially insured patients who do not have coverage for XHANCE due to a requirement from their insurance provider for a prior authorization may receive their initial prescription for an out-of-pocket cost of $0.

Preferred Pharmacy locator

Find local specialty pharmacies within the XHANCE PPN.

Select a state:

Results: 0

Review resources for your practice and your patients.

Learn details about the XHANCE savings card.

Get Details

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:
Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local Nasal Effects: epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
Close monitoring for glaucoma and cataracts is warranted.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
Patients with major risk factors for decreased bone mineral content should be monitored and treated with established standards of care.

ADVERSE REACTIONS:
The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS:
Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS:
Hepatic impairment. Monitor patients for signs of increased drug exposure.

INDICATION AND USAGE: XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

Please see full Prescribing Information, including Instructions for Use.